Stoke Therapeutics Inc
NASDAQ:STOK
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Stoke Therapeutics Inc
Other Long-Term Assets
Stoke Therapeutics Inc
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Stoke Therapeutics Inc
NASDAQ:STOK
|
Other Long-Term Assets
$227k
|
CAGR 3-Years
-28%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Long-Term Assets
$10.7B
|
CAGR 3-Years
24%
|
CAGR 5-Years
17%
|
CAGR 10-Years
25%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Long-Term Assets
$6.8B
|
CAGR 3-Years
12%
|
CAGR 5-Years
6%
|
CAGR 10-Years
15%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Long-Term Assets
$12.7B
|
CAGR 3-Years
29%
|
CAGR 5-Years
18%
|
CAGR 10-Years
23%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Long-Term Assets
$4.1B
|
CAGR 3-Years
35%
|
CAGR 5-Years
35%
|
CAGR 10-Years
64%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Long-Term Assets
$5.9B
|
CAGR 3-Years
43%
|
CAGR 5-Years
44%
|
CAGR 10-Years
29%
|
|
Stoke Therapeutics Inc
Glance View
Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. The company is headquartered in Bedford, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2019-06-19. The company focuses to treat the underlying causes of severe genetic diseases by upregulating protein expression. The company is developing antisense oligonucleotide (ASO) medicines that target ribonucleic acid (RNA) and modulate precursor-messenger RNA (pre-mRNA) splicing to upregulate protein expression where needed and with appropriate specificity to near normal levels. The company focuses to develop the precision medicine platform to target the underlying cause of a spectrum of genetic diseases in which the patient has healthy copy of a gene and mutated copy that fails to produce a protein essential to health. The company utilizes its technology platform, Targeted Augmentation of Nuclear Gene Output (TANGO) to design ASOs to upregulate the expression of protein by individual genes in a patient. Its product candidate, STK-001, is offered to treat Dravet syndrome. Its research platform is designed to address protein deficiency.
See Also
What is Stoke Therapeutics Inc's Other Long-Term Assets?
Other Long-Term Assets
227k
USD
Based on the financial report for Dec 31, 2025, Stoke Therapeutics Inc's Other Long-Term Assets amounts to 227k USD.
What is Stoke Therapeutics Inc's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
3%
Over the last year, the Other Long-Term Assets growth was -69%. The average annual Other Long-Term Assets growth rates for Stoke Therapeutics Inc have been -28% over the past three years , 3% over the past five years .
